MRUS News and Press, Merus N.V. From 08/05/21

Merus (NASDAQ:MRUS): Q2 GAAP EPS of -$0.71 misses by $0.13. Revenue of $12.38M (+103.0% Y/Y) beats by $4.32M. Press Release For further details see: Merus EPS misses by $0.13, beats on revenue

UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 21, 2021 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced the novel mechani...

Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundberg...

Photo by goir/iStock via Getty Images Merus jumps on Citi upgrade Merus (MRUS) shares have climbed ~5.4% in early trading after Citi analyst Yigal Nochomovitz upgraded the stock to buy from neutral. The price target of $31.00 per share implies a premium of ~49.9%. Citing dataset pre...

Ra Medical Systems (RMED) +56%.Liminal BioSciences (LMNL) +42%.NextDecade Corporation (NEXT) +30%.U.S. Concrete (USCR) +28% as Vulcan Materials buys the Company in $1.3B deal.QTS Realty Trust (QTS) +20% on being acquired by Blackstone funds for $78/share.ChromaDex Corporation (CDXC)...

Merus ([[MRUS]] +1.6%) announces positive interim efficacy data from the phase 1/2 eNRGy trial of bispecific antibody zenocutuzumab ((Zeno)) in patients with NRG1+ cancers.61 patients with NRG1+ cancer have been enrolled, including 45 patients evaluable for response as of the data cutoff date...

-  61 patients with NRG1+ cancer have been enrolled, including 45 patients evaluable for response as of the April 13, 2021 data cutoff date -  Encouraging early clinical activity observed, with confirmed responses in 5 of 12 patients with pancreatic cancer (42%) and in...

ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundberg...